Investors looking to supercharge their portfolios often benefit from a broader stock search. One simple way to do that is to look at year-ahead earnings forecasts. Our hunt for the seven best stocks poised for magnificent earnings growth next year brought up names such as Vericel (VCEL) and Alcoa (AA) — stocks far less obvious than Meta (META), Amazon (AMZN), Tesla (TSLA) or the other megacap leaders that dominate the market.
↑
X
What Are The Magnificent Seven Stocks?
Seven Best Stocks For Magnificent Earnings Growth
TG Therapeutics (TGTX): A commercial-stage biopharmaceutical company, TG sells a multiple sclerosis treatment called Briumvi, which has been driving growth. On a per-share basis, analysts forecast TG will see a 1,870% surge in earnings in 2025, recovering from a sharp decline this year. The company has made a recent turn to profits. Sales are seen growing 41% in 2024 and 64% in 2025. TG Therapeutics stock shows a Composite Rating of 78 and RS Rating of 98. It has surged 105% so far this year. Shares tumbled on an earnings miss earlier in November. But they made a new high on Monday before paring gains.
Alcoa (AA): The aluminum company is returning to growth after a challenging period. In October, Alcoa delivered its second straight quarter of positive earnings after a seven-quarter slump. Analysts expect Alcoa to swing to positive earnings in full-year 2024, followed by a 336% leap next year. Sales are seen rebounding 10% this year and growing 5.5% next year, after the company completed its Alumina acquisition in August. Alcoa stock holds a Composite Rating of 80 and RS Rating of 92. It has advanced almost 40% so far this year as investors digest improving fundamentals.
Biopharma Vericel, Medical Firm RadNet
Vericel (VCEL): This biopharmaceutical company makes products for sports medicine and severe burns. Vericel has an uneven profit track record. However, it enjoys a favorable growth outlook. Analysts expect a strong fourth quarter to push Vericel to positive earnings in full-year 2024, after three years of earnings declines. Analysts project Vericel earnings per share will grow almost fourfold next year, vaulting 276%, as sales jump 23%. Vericel stock earns a Composite Rating of 80 and RS Rating of 87. It scored an earnings breakout to multi-year highs in November. VCEL stock is up 65% so far this year. Trading volume is on the lighter side.
RadNet (RDNT): RadNet runs diagnostic imaging facilities. Forecasts call for the medical company to grow earnings per share 179% next year, following a big rebound in 2024. RadNet saw earnings crumble in 2022 and 2023. Analysts see sales rising 12% in 2024 and 8% next year. RadNet stock earns a Composite Rating of 85 and RS Rating of 96. It has rocketed 135% so far this year. Shares gapped up 19% to highs on Nov. 11 amid strong earnings. The company hiked full-year earnings guidance after AI drove 76% digital health revenue growth in the third quarter.
GE Vernova (GEV): Spun out as an independent company in April, GE Vernova houses the energy assets of the old General Electric. This once-embattled business is seeing end markets recover. GE Vernova has guided growth across business segments, earning it a place in the best stocks list. GE Vernova delivered a big earnings miss for Q3 on Oct. 23, but reaffirmed 2024 guidance. Analysts expect earnings to boom 174% per share next year on 6% sales growth. GE Vernova stock flourishes a Composite Rating of 92 and RS Rating of 98. GEV has more than doubled since its April debut.
Semtech, Lumentum Join Best Stocks List
Semtech (SMTC): A new entry to the best stocks list, Semtech supplies high-performance semiconductors and other products for the infrastructure, industrial and consumer markets. Analysts expect Semtech earnings per share to boom 142% next year, after a strong comeback in 2024. Semtech saw an earnings collapse in 2023. Sales are seen rising 3% this year and jumping 21% next year. Semtech stock holds a Composite Rating of 71 and RS Rating of 97. It has more than doubled so far this year, up 144%. SMTC stock soared more than 10% on earnings late Monday. Shares made a new high in the regular session, closing at two-year-plus highs. Estimates will be under review after the results.
Lumentum (LITE): The company makes products that enable optical networking and laser applications. Lumentum is poised for an earnings comeback starting in the current quarter after three years of hefty declines, helping it join the best stocks list. Analysts project a earnings to recover 55% per share for the full year, which ends in June. They expect a further 136% earnings boom next year on a 28% sales surge. Lumentum stock flourishes a Composite Rating of 78 and RS Rating of 96. It rocketed to two-year-plus highs earlier in November after posting a far narrower-than-expected loss for its first quarter. LITE stock made a new high on Monday.
Universe of S&P 500, S&P 400 and S&P 600 Stocks
A little background on IBD’s process to select the best stocks for magnificent earnings growth:
We began our screening process with the S&P Composite 1500 index, which aggregates the S&P 500, S&P MidCap 400 and S&P SmallCap 600 companies. We chose this index, in part, because it avoids less-liquid, lower-priced and lower-quality names, while efficiently measuring the total U.S. stock market.
Then we limited the stocks on our best stock list to those showing FactSet consensus ratings of overweight or buy, which means analysts expect them to outperform industry peers. Next we further winnowed down the list, setting up a double hurdle: The stocks had to enjoy some of the strongest FactSet earnings growth estimates for the following fiscal year, while also earning high IBD ratings, in terms of their Composite Rating and RS Rating.
The resulting seven best stocks for outsize earnings growth are a quite different set from the Magnificent Seven stocks. At the same time, these stocks are worth watching as much as any of the Mag Seven stocks given their outperformance potential.
To find other ideas for the best stocks to buy or watch, check out IBD Stock Lists and other IBD content.
YOU MAY ALSO LIKE:
Why This IBD Tool Simplifies The Search For Top Stocks
Best Growth Stocks To Buy And Watch
IBD Digital: Unlock IBD’s Premium Stock Lists, Tools And Analysis Today
Looking For Market Insights? Check Out Our IBD Live Daily Segment